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Customized Order-Entry Sets Can Prevent  
Antiretroviral Prescribing Errors: A Novel Opportunity  
For Antimicrobial Stewardship
Yi Guo, PharmD; Philip Chung, PharmD, BCPS; Caryn Weiss, ANP;  
Keith Veltri, PharmD; and Grace Y. Minamoto, MD
ABSTRACT
Background: Patients with human immunodeficiency virus 
(HIV) infection on antiretroviral (ARV) therapy are at increased 
risk for medication errors during transitions of care between 
the outpatient and inpatient settings. This can lead to treat-
ment failure or toxicity. Previous studies have emphasized 
the prevalence of medication errors in such patients, but few 
have reported initiatives to prevent errors from occurring.
Methods: The study was conducted in a 1,400-bed health 
care center with a state-designated Acquired Immunodeficiency 
Syndrome (AIDS) Center in the Bronx, New York. The anti-
microbial stewardship team and HIV specialists developed 
customized order-entry sets (COES) to guide ARV prescrib-
ing and retrospectively reviewed their effect on error rates of 
initial ARV orders for inpatients before reconciliation. Patient 
records were reviewed in six-month periods before and after 
intervention. The student’s t-test or Mann–Whitney U test was 
used to compare continuous variables; chi-square or Fisher’s 
exact test was used for categorical variables. 
Results: A total of 723 and 661 admissions were included in 
the pre-intervention and post-intervention periods, respectively. 
Overall, error rates decreased by 35% (38.0% to 24.8%, P < 0.01) 
with COES. Wrong doses and drug interactions decreased by 
more than 40% (P < 0.005). Error reductions were observed 
in protease inhibitor (PI)-based (43.6% versus 28.7%, P < 0.01) 
and non–PI-based (38.0% versus 24.4%, P = 0.02) regimens with 
COES. A shift in predominant drug-class errors was observed 
as there was a trend toward increased usage of non-PI regimens 
post-intervention. Admission in the pre-intervention period 
(adjusted odds ratio [AOR], 1.79; 95% confidence interval 
[CI], 1.39–2.31) and use of PI-based regimens (AOR, 2.03; 
95% CI, 1.53–2.70) remained significantly associated with ARV 
prescribing errors after controlling for confounding factors. 
Conclusion: Detailed COES improved ARV prescribing 
habits, reduced the potential for prescribing incorrect regi-
mens, and can prove useful and cost-effective where HIV-
specific medication reconciliation is unavailable. 
Dr. Guo and Dr. Chung are Clinical Pharmacy Managers in the 
Department of Pharmacy and Assistant Professors in the Division 
of Infectious Diseases at Montefiore Medical Center and the Albert 
Einstein College of Medicine in Bronx, New York. Caryn Weiss is a 
Nurse Practitioner in the Department of Medicine, Division of Infec-
tious Diseases, at Montefiore and Einstein. Dr. Veltri is a Clinical 
Pharmacy Manager in the Department of Pharmacy at Montefiore 
and Einstein and Associate Professor at Touro College of Pharmacy 
in New York, New York. Dr. Minamoto is an Attending Physician 
and Associate Professor in the Department of Medicine, Division of 
Infectious Diseases, at Montefiore and Einstein.
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INTRODUCTION
At least 1.5 million preventable adverse drug events occur 
each year in the U.S. because of medication errors.1 Several 
studies have found that many of these occur during the transi-
tion of care between the outpatient and inpatient settings.2–5 
Individuals infected with human immunodeficiency virus 
(HIV) are particularly vulnerable during periods of transition.6 
Prescribing errors involving patients receiving antiretroviral 
(ARV) therapy are significantly higher than rates reported 
in individuals without HIV infection.3,4,7 It is estimated that 
more than 84% of hospitalized patients with HIV infection 
may experience an ARV-related error.7 The etiology of these 
errors is often multifactorial and includes lack of provider 
knowledge or familiarity with the disease state,1 complexity 
of regimens, and frequent regimen revisions. The widespread 
use of potent combination ARV therapy has reduced hospi-
talizations for opportunistic infections and other HIV-related 
conditions,8 has increased life expectancy for those with HIV 
infections, and has resulted in an increase in hospitalizations 
for other comorbid medical problems. Increasingly, medical 
staff members without formal training in HIV management or 
infectious diseases have been providing inpatient care to HIV 
patients. In addition, comorbidities may increase the potential 
for clinically significant drug interactions and polypharmacy.9 
ARV prescribing errors may lead to treatment failure, develop-
ment of resistance, and suboptimal dosing or drug toxicity. It is 
therefore crucial that these patients’ therapies are appropriately 
continued during their hospitalizations. 
Many studies have emphasized the prevalence of medica-
tion errors in hospitalized patients with HIV infection.1–4,7,10–26 
Frequently cited errors include medication omission, dosing 
errors, incorrect scheduling, and drug interactions; errors are 
associated with all major drug classes, including nucleos(t)ide 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). 
In our institution, monthly in-service training sessions for 
house staff, physician assistants, and pharmacists were con-
ducted along with the provision of reference materials. An ARV 
medication chart was developed, which included routine doses; 
interactions of commonly used medications as well as other 
ARV medications; weight and renal dosing recommendations; 
and contraindications for use of other medications. Pop-up alerts 
in the computerized prescriber order-entry system (CPOE; 
Disclosure: The authors report no commercial or financial interests 
in regard to this article.
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Customized order-entry sets within the computerized prescriber order-entry system offer guidance on drug interactions and 
dosage for specific settings—in these examples, when prescribing atazanavir (A) and on dose adjustment for renal insufficiency 
for prescribing coformulated emtricitabine and tenofovir (B).
Figure 1  Examples of Customized Order-Entry Sets
A
B
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CareCast version 3.04) were added to remind ordering pre-
scribers of the need for complete regimens, deferring ordering 
until correct regimens could be confirmed. ARV orders are 
routinely reviewed by the AIDS Center nurse practitioner and 
hospital pharmacy staff members, who alert prescribing staff 
to the need for order corrections. However, errors for ARV 
orders can still occur.
The antimicrobial stewardship team and HIV specialists 
determined that an enhanced system would be necessary 
to prevent ARV errors before they actually occur. In 2011, 
customized order-entry sets (COES) for ARV medications 
were developed and implemented in our institution to further 
prevent ARV-related errors prospectively in addition to CPOE 
and periodic educational in-service sessions (Figure 1). CPOE 
with COES prevents prescribers from ordering incomplete 
regimens, provides dosing guidance based on renal function 
and concomitant drug therapy, and flags contraindicated drug 
interactions prior to the commission of potential ARV errors in 
real time. The objective of this study was to evaluate the effect 
of CPOE with COES on error rates of initial ARV orders for 
inpatients with HIV infection prior to reconciliation of orders 
by HIV clinical specialists and pharmacists.
METHODS
Study Population and Setting 
Our institution is a 1,400-bed academic health care system in 
the Bronx, New York, with more than 90,000 inpatient admis-
sions annually, of which more than 1,700 are for HIV-infected 
individuals. In a Bronx population of nearly 1.4 million people, 
more than 23,000 are living with HIV.27 The system is one of 
the few regional hospitals with a dedicated team consisting of a 
medical director, a nurse practitioner, and social workers who 
monitor the care of any patient admitted with the diagnosis 
of HIV. Our institution does not maintain a dedicated HIV 
patient-care unit; rather, patients are cared for throughout the 
hospital on units appropriate to their medical or surgical needs.
The study was approved by the Montefiore Medical Center/
Albert Einstein College of Medicine institutional review board. 
Data Collection
The time frames reviewed were September 2010 to February 
2011 (a six-month period before implementation of the COES 
in August 2011) and September 2011 to February 2012. The 
charts of all hospitalized adult patients (older than 18 years 
of age) for whom ARVs were ordered were retrospectively 
reviewed. Patients without HIV infection who were prescribed 
lamivudine or tenofovir for hepatitis B infection were excluded. 
Patient characteristics obtained included age, sex, race, medical 
service, HIV viral load, CD4 cell count, creatinine clearance 
(estimated based on the Cockcroft–Gault equation), ARV regi-
mens initially prescribed, and medications with the potential 
for drug–drug interactions. The CD4 cell counts and HIV viral 
load results used in this study were those values within six 
months of and closest to the dates of admission. 
ARV regimens were classified as consisting of a single-
formulation preparation (e.g., emtricitabine/tenofovir/efavirenz 
[Atripla, Gilead Sciences]), protease inhibitor (PI)-based, or 
non–PI-based. Prescribing errors were categorized as incom-
plete regimens, incorrect ARV drug, incorrect dosing of at 
least one ARV drug, incorrect scheduling frequency, incorrect 
dosing of at least one drug for renal insufficiency, and regimens 
that included an agent with interaction potential with another 
prescribed drug.
Prescribing errors were enumerated differently based on 
analysis parameters. For determination of admissions with any 
ARV errors, one or more prescribing error(s) within an ARV 
regimen was tallied as one admission with ARV prescribing 
error(s). For determination of a specific type of error within 
an ARV regimen, one or more error(s) of a specific type (e.g., 
wrong dose) was counted as one type-specific error against a 
regimen. Finally, for determination of a specific type of error 
based on drug classes, each error was tallied individually. 
Analysis
Chi-square and Fisher’s exact tests as appropriate were 
used to assess associations between categorical variables; the 
Mann–Whitney test was used to compare continuous variables 
among groups. Multivariate logistic regression analysis was 
performed to determine variables independently associated 
with ARV prescribing errors. Variables with a P value of less 
than 0.20 on univariate analysis, intervention period, and 
internal medicine as admitting service were included in the 
logistic regression model. A two-tailed P value of less than 0.05 
represented statistical significance for all statistical compari-
sons. Statistical analyses were performed using SAS version 
9.4 (SAS Institute Inc., Cary, North Carolina).
RESULTS
A total of 1,486 and 1,316 admissions involved patients 
with a diagnosis of HIV during the pre-intervention and post- 
intervention periods, respectively. Among these hospitaliza-
tions, ARVs were prescribed in 723 admissions involving 519 
patients in the pre-intervention period and 661 admissions 
involving 489 patients in the post-intervention period. Patient 
demographics for the two study periods were comparable 
(Table 1). The median age of the study population was approxi-
mately 50 years; approximately 46% of the patients were female. 
Nearly three-quarters of the study population identified them-
selves as either African-American or multiracial. The majority 
of study patients (more than 70%) were admitted to an internal 
medicine service, while relatively fewer patients were admitted 
to a surgical service or critical-care unit. Forty-nine percent and 
54% of patients had undetectable viral loads (40 copies/mL or 
less) during the pre-intervention and post-intervention periods, 
respectively. CD4 counts were more than 200 cells/mcL in 
approximately 60% of patients and more than 500 cells/mcL 
in more than 25% of patients. Types of regimens prescribed 
during hospital admissions in the pre-intervention and post-
intervention periods were similar; PI-based regimens were 
the most commonly prescribed during both study periods 
(Table 1, Figure 2).
Prior to the initiation of COES, ARV prescribing errors of any 
type were observed in 275 admissions (38.0%). Use of COES, 
along with prescriber education, reduced ARV prescribing 
errors in 164 admissions (24.8%), representing an error reduc-
tion rate of 34.7% (P < 0.01). The most commonly observed 
errors were use of an incorrect ARV dose (13.8%) and drug 
interaction with an ARV (10.2%) during the pre-intervention 
Customized Order-Entry Sets Can Prevent Antiretroviral Prescribing Errors
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period. With the use of COES, reductions of 49% in wrong 
dose and 43% in drug-interaction errors were observed. COES, 
however, did not significantly reduce errors of prescribing 
the incorrect ARV (1.8% pre-intervention versus 1.2% post-
intervention, P = 0.39) or wrong frequency (7.6% versus 6.1%, 
P = 0.29). Figure 3 further details changes in error rates 
between the pre-intervention and post-intervention periods. 
Customized Order-Entry Sets Can Prevent Antiretroviral Prescribing Errors
When stratified by regimen type, signifi-
cant error reductions in PI-based regimens 
(43.6% versus 28.7%, P < 0.01) and non–
PI-based regimens (38.0% versus 24.4%, 
P = 0.02) were observed with use of COES. 
A greater than 50% reduction in single-pill 
combination ARV errors was also observed, 
albeit not statistically significant due to the 
small number of patients on this type of 
therapy (8.6% versus 3.9%, P = 0.35). 
When stratified by drug class, a change 
in the composition of prescribing errors was 
observed between the two study periods 
(Figure 4). Prior to the introduction of COES, 
PI errors were the most common among the 
five ARV classes, accounting for 49.8% of 319 
errors. Errors involving NRTIs were the 
next most common at 40.7%. With the use of 
COES, NRTI prescribing errors became the 
most common (53.9% of 167 errors), followed 
by PI errors (34.1%).  The percentage of 
errors involving the remaining three classes 
of ARVs was not significantly different with 
or without implementation of COES. 
Closer examination of different types of 
errors within each drug class revealed wrong 
dose/frequency and drug-inter action errors 
with protease inhibitors were significantly 
reduced after the introduction of COES 
(Table 2). Errors related to NRTI dose 
adjustment due to renal dysfunction also 
significantly declined. Prescribing errors 
associated with NNRTIs, chemokine (C-C 
motif) receptor 5 (CCR5) inhibitors, and integrase inhibitors 
did not change significantly between the two study periods, 
most likely because of the small number of patients using 
these drug classes. 
In addition to intervention period and internal medicine 
as admitting service, the variables of race, viral load greater 
than 40 copies/mL, and ARV regimen (all with P values of 
less than 0.20 on univariate analysis, Table 1) were included 
in the logistic regression analysis model. After controlling for 
potential confounders, pre-intervention period (adjusted odds 
ratio [AOR], 1.79; 95% confidence interval [CI], 1.39–2.31; 
P < 0.01) and PI-based ARV regimen (AOR, 2.03; 95% CI, 
1.53–2.70, P < 0.01) remained significantly associated with 
ARV prescribing errors (Table 3).
DISCUSSION
It is becoming increasingly difficult for physicians to stay 
abreast of changes in HIV drug management. The expanding 
number of ARVs approved by the Food and Drug Administration 
and the potential number of drug combinations, as well as 
frequent changes in clinical practice guidelines, can be over-
whelming to medical providers. Improved measures to assist 
prescribers with error prevention are much needed.
This study demonstrated that ARV prescribing errors in an 
inpatient setting can be substantially reduced by CPOE with 
COES. More importantly, COES prevented a large number of 
Table 1  Demographics of Hospitalized Patients With Human 
Immunodeficiency Virus Infection on Antiretroviral Therapy  






Median age, years (range) 51 (18–88) 52 (22–93) 0.78
Female, n (%) 333 (46.1) 315 (47.7) 0.55
Race, n (%)
0.17
African-American 318 (44.0) 333 (50.4)
Multiracial 218 (30.2) 178 (26.9)
Hispanic 63 (8.7) 50 (7.6)
Caucasian 62 (8.6) 56 (8.5)
Other 62 (8.6) 44 (6.7)
Admitting service, n (%)
0.32
Internal medicine 528 (73.0) 486 (73.5)
Surgery 50 (6.9) 43 (6.5)
Critical care 2 (0.3) 7 (1.1)
Other* 143 (19.8) 125 (18.9)
Median length of stay, days (range) 5 (1–135) 5 (1–126) 0.41
Viral load > 40 copies/mL, n (%) 312/616 (50.7) 272/592 (46.0) 0.10
CD4 count < 200 cells/mcL, n (%) 257/671 (38.3) 230/623 (36.9) 0.61
PI-based ARV regimen 493 (68.2) 428 (64.8) 0.10
* “Other” includes services such as family medicine, oncology, etc. 
ARV = antiretroviral; PI = protease inhibitor
ARV = antiretroviral therapy; PI = protease inhibitor
Figure 2 Types of Regimens Prescribed During  
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these errors prior to patients receiving their first ARV doses 
during hospitalization. To our knowledge, this is the largest 
and only study to date in a region of high HIV prevalence that 
reviews the effects of such an ordering system on the reduc-
tion of potential medication errors before they occur, rather 
than rectifying mistakes after they have transpired. The multi-
disciplinary collaboration between the departments of infec-
tious diseases, pharmacy, and information technology made the 
CPOE with COES possible for our institution. We constructed 
a COES for each ARV that is simple in design (Figure 1) and 
can be easily reproduced and implemented by most small or 
large institutions with CPOE. These ordering screens can be 
especially important for reducing ARV errors if the institution 
does not have designated pharmacists or medical staff trained 
in infectious diseases to review ART on a daily basis. 
Overall, COES reduced errors of any type by 34.7%, primarily 
due to reductions in PI and renal dosing errors. Error rates 
were significantly reduced for incomplete regimens, incorrect 
dose, and drug interactions. There was no significant impact 
on incorrect ARV choice and on dosing frequency, but a trend 
toward reduction was observed. The lack of impact on incorrect 
ARV choice is likely multifactorial in etiology. COES cannot 
distinguish between the choices of protease inhibitors (e.g., 
atazanavir [Reyataz, Bristol-Myers Squibb] versus daruna-
vir [Prezista, Janssen]), NRTIs (e.g., emtricitabine/tenofo-
vir [Truvada, Gilead Sciences] versus lamivudine/abacavir 
[Epzicom, ViiV Healthcare]), or NNRTIs (e.g., nevirapine 
[Viramune, Boehringer Ingelheim] versus efavirenz [Sustiva, 
Bristol-Myers Squibb]).  
In almost all cases, ARV regimens of hospitalized patients 
are initiated by outside HIV care providers. The occasional 
lack of access to the correct ARV regimen, especially for those 
patients whose records are not part of the hospital’s medical 
record system, poses challenges for inpatient house staff. 
Prompt communication with the primary HIV care provider 
will help to reduce the number of errors for ARV choice and 
address the inability of COES to make intra-class distinc-
tions. Incorrect creatinine clearance calculations may have 
contributed to incorrect dosing frequency errors. Further 
education is needed on using the Cockcroft–Gault equation 
for creatinine clearance calculations in order to reduce error 
in dosing frequency. 
Error rates for PI-based and non–PI-based regimens simi-
larly improved after the introduction of COES (pre-interven-
tion: PI-based, 43.6%, non–PI-based, 38%; post-intervention: 
PI-based, 28.7%, non–PI-based, 24.4%). A number of studies4,21–23 
have found that the ordering of PIs is more likely to be associ-
Customized Order-Entry Sets Can Prevent Antiretroviral Prescribing Errors
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CCR5 = chemokine (C-C motif) receptor 5 inhibitors; PI = protease inhibitor; 
NNRTIs = non-nucleoside reverse transcriptase inhibitors; NRTIs = nucleos(t)ide 
reverse transcriptase inhibitors
Figure 4  Compositions of ARV Errors During the  
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ated with errors as a result of multiple available formulations, 
the use of ritonavir for so-called boosted regimens, and inter-
actions with proton pump inhibitors, histamine receptor 2 
blockers, and statins. This is consistent with findings from 
this study that suggest PI-based regimens were independently 
associated with ARV prescribing errors (Table 3). Possibly, the 
decrease in concomitant use of potentially interacting drugs 
and prescribers’ increased familiarity with ritonavir’s use as a 
booster may have contributed to a reduction in PI-associated 
errors after the introduction of COES. The reduction in the 
percentage of PI-associated errors likely accounts for the 
increase in the proportion of NRTI errors. 
The prescribing of single-pill formulations such as efavirenz/
emtricitabine/tenofovir and emtricitabine/rilpivirine/tenofo-
vir (Complera, Gilead Sciences) among hospitalized patients 
remained just over 10% between the two study periods. With 
a decreased pill burden and potential for increased medica-
tion adherence, these formulations can be expected to be 
prescribed more frequently. However, their use in persons 
with renal insufficiency will be limited. Errors associated with 
prescribing of these formulations occurred in 
our population precisely for this reason. In a 
prospective French study involving HIV sero-
positive hemodialysis patients, underdosing 
and overdosing errors occurred among 59% 
of ARV medications prescribed.18 
A variety of interventions to reduce ARV 
prescribing errors have been investigated. 
Several studies are based primarily on the 
intervention by the pharmacy, in which 
inpatient pharmacy staff members reconcile 
outpatient regimens with inpatient orders 
and often consult the patients’ medical care 
providers or families.3,9,11,21,23 Other studies 
have used a multidisciplinary approach that 
typically included a combination of com-
puterized alerts, physician and pharmacy 
review, and educational measures. Yehia 
et al. used such an approach with a CPOE 
with drug–drug interaction alerts and cal-
culated creatinine clearance but did not flag 
incomplete regimens or errors in medication 
dosing or scheduling.20 In another study, a 
primarily pharmacy-driven resolution was 
achieved through daily medication review, 
super imposed on education, CPOE alerts, 
and formulary conversions.22 
With the goal of achieving optimal clini-
cal outcomes related to antimicrobial use 
and minimizing adverse drug events and the 
potential for drug resistance, antimicrobial 
stewardship is well positioned to intervene in 
the problem of ARV prescribing errors. This 
approach was recently reported by Sander 
et al., in which an intervention that included 
education, modification of electronic records, 
collaboration with infectious disease (ID) 
specialists, and prospective auditing by ID 
clinical pharmacists of HIV-related medica-
tion orders resulted in a significantly higher (74% versus 
35%) post-intervention error resolution rate.25 In our study, 
the stewardship effort was further enhanced by the use of 
COES superimposed on established educational tools and 
multi disciplinary communication between prescribers, ID 
specialists, and ID pharmacists. 
CPOE systems have been observed to both reduce and 
facilitate medication errors.21,28 The potential for ordering 
errors is likely to be increased for unusual ARV regimens, 
especially in the highly treatment-experienced patient with 
multiple genotypic resistance mutations, and with the ordering 
of nonformulary ARVs. Therefore, to reduce such ordering 
errors, COES must be constantly updated and HIV clinical 
specialists and pharmacists must be readily available. 
There are a number of potential limitations to this study. The 
retrospective nature of the review may have allowed unrec-
ognized bias. The study is based on data from a single large 
tertiary-care teaching hospital in an urban setting; the results 
may not be applicable to all hospital settings. Multiple hospi-
talizations per patient may have occurred during each study 
Table 2  Prescribing Errors During Pre-Intervention and Post-Intervention 









Wrong dose 34 (4.7) 26 (3.9) −17.0 0.51
Wrong frequency 21 (2.9) 27 (4.1) +41.4 0.31
Not renally dosed 68 (9.4) 35 (5.3) −43.6 < 0.01 b
Drug interaction 6 (0.8) 2 (0.3) −62.5 0.29
NNRTI errors
Wrong dose 9 (1.2) 2 (0.3) −75.0 0.07
Wrong frequency 4 (0.6) 4 (0.6) 0.0 1.00
Drug interaction 5 (0.7) 1 (0.2) −71.4 0.22
PI errors
Wrong dose 65 (9.0) 16 (2.4) −73.3 < 0.01 b
Wrong frequency 30 (4.2) 9 (1.4) −66.7 < 0.01 b
Drug interaction 63 (8.7) 32 (4.8) −44.8 < 0.01 b
CCR5 errors
Wrong dose 1 (0.1) 2 (0.3) +200.0 0.61
Wrong frequency 0 (0.0) 0 (0.0) 0.0 1.00
Drug interaction 1 (0.1) 3 (0.5) +400.0 0.35
Integrase inhibitor errors
Wrong dose 1 (0.1) 3 (0.5) +400.0 0.35
Wrong frequency 8 (1.1) 5 (0.8) −27.3 0.58
Drug interaction 1 (0.1) 0 (0.0) −100.0 1.00
a Data presented as n (%) 
b Statistically significant
CCR5 = chemokine (C-C motif) receptor 5 inhibitor; NNRTI = nonnucleoside reverse-transcriptase 
inhibitor; NRTI = nucleos(t)ide reverse-transcriptase inhibitor; PI = protease inhibitor
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period as well as during both study periods, but each admission 
presented as an opportunity for ARV ordering. Patient charac-
teristics (such as degree of renal insufficiency, comorbidities, 
or reasons for hospitalization) before and after the introduction 
of COES may have differed in unrecognized ways. The pattern 
of ARV prescribing or prescriber characteristics may have 
changed over time. Familiarity with ARVs and management 
may have differed between the two periods studied. Possibly, 
newer ARVs and formulations and increased ARV resistance 
between the two populations studied may have confounded our 
analysis of the impact of COES. We attempted to control for 
possible seasonal effects on hospital admissions by reviewing 
the same period of the year; we also intended that this would 
control for the experience of medical residents, who comprise 
a significant proportion of prescribers at our institution. 
Although ARV medication errors cannot be prevented com-
pletely, health care providers must exercise caution when 
prescribing ARVs. It is sobering to consider that ARV regimens 
incorrectly prescribed for even brief periods could have both 
short- and long-term consequences with adverse effects, viral 
resistance, and clinical outcomes. A multifaceted approach 
to error prevention under the auspices of an antimicrobial 
stewardship program should include education with updated, 
user-friendly tools to increase awareness, active real-time 
auditing of ARV ordering, consultation with HIV ID specialists 
or dedicated clinical pharmacists, and effective reconcilia-
tion of inpatient orders with outpatient records. Upon patient 
discharge, it is also crucial to ensure that the patient will be 
provided with prescriptions for the correct ARV regimens 
during the transition in care. 
In conclusion, COES can further prevent ARV prescribing 
errors before they occur among hospitalized patients with HIV 
infection in large urban areas with high HIV prevalence and 
may prove to be a useful, stand-alone, and cost-efficient means 
of reducing ARV prescribing errors in hospitals that do not 
have HIV clinical specialists and pharmacists. Vigilance must 
be maintained to keep the ordering system updated to ensure 
correctness in prescribing, especially as newer medications 
and formulations become available and drug interactions are 
better described. Future studies might focus additionally on 
the use of COES in other health care settings, such as long-
term care facilities, clinics, ambulatory surgical centers, and 
dialysis centers, and on the use of medications for primary and 
secondary prophylaxis of opportunistic infections. 
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African-American 0.96 (0.74–1.23)  0.73
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